Roxanne Reger, MS

Roxanne Reger, MS

Assistant Professor

College of Medicine
5701 Airport Road, Module C
Temple, TX   76502

Phone: 254.771.6857
Fax: 254.771.6839

Education and Training

Roxanne Reger is a research assistant professor of molecular and cellular medicine at the Institute for Regenerative Medicine located in Temple, Texas. She received her BA in psychology from the State University of New York in 1981, and her MS in psychology from Tulane University in 1986 working with Dr. Arnold Gerall. In 2000 she accepted a position at the Center for Gene Therapy at Tulane University Health Science Center, working with Dr. Darwin Prockop. She joined the faculty at Texas A&M University Health Science Center in July 2008.

Research Interests

Mesenchymal stem/progenitor cells:

Mesenchymal stem/progenitor cells (MSCs) are isolated from the bone marrow of adults by their adherence to tissue culture plastic ware. However, the conditions under which MSCs are isolated and expanded can yield variable populations of these cells with different properties. This results in discrepancies in the literature from the basic biology through the clinical applications of MSCs. Our group is addressing this variability though our NIH/NCRR grant to distribute well characterized, standardized preparations of MSCs from humans, rats and mice to researchers throughout the world. The preparation and distribution of MSCs through this grant is carried out in the Stem/Progenitor Cell Standardization Core (SPCS), which Reger directs.

Translational medicine:

The relative ease with which MSCs can be isolated and the results from numerous studies pointing to the therapeutic potential of MSCs to treat a myriad of injuries and diseases make them attractive candidates for human therapies. In the SPCS, we are developing and testing methods of scaling up production of MSCs while maintaining their desired characteristics to be incorporated in our Good Manufacturing Practice facility, where cells will be produced for Clinical Trials.

Although cells can and are delivered systemically via the vascular system in many therapeutic indications, there may be instances, especially in the Central Nervous System, where it would be desirable to deliver the cells exactly where they are needed. We are developing controlled-rate methods for targeted delivery of cell therapies that will both maximize cell viability and minimize further injury to the recipient tissue. Animal models of brain and spinal cord injury are used to examine both the therapeutic potential of the cells and the damage caused by the delivery methods. 

Selected Publications

Sekiya, I., Larson, B.L., Vuoristo, J.T., Reger, R.L. and Prockop, D.J. (2005)  "Comparison of effect of BMP-2, -4, and -6 on in vitro cartilage formation of human adult stem cells from bone marrow stroma."  Cell Tissue Res. 320(2):  269-76. Epub 2005 Mar 19.

Peister, A., Zeitouni, S., Pfankuch, T., Reger, R.L., Prockop, D.J., Raber, J. (2006)  "Novel object recognition in Apoe(-/-) mice improved by neonatal implantation of wild-type multipotential stromal cells."  Exp Neurol. 201(1):  266-9. Epub 2006 Jun 30.

Lee, R.H., Seo, M.J., Reger, R.L., Spees, J.L., Pulin, A.A., Olson, S.D., Prockop, D.J. (2006)  "Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice."  Proc Natl Acad Sci USA, 103(46):17438-43.  Epub 2006 Nov 6.

Wolfe, M., Pochampally, R., Swaney, W., Reger, R.L.  (2008)  "Isolation and culture of bone marrow-derived multipotent stromal cells (hMSCs)."  Methods in Mol. Biol. 449: 3-25.

Reger, R.L., Tucker, A.H., Wolfe, M.R. (2008)  "Differentiation and characterization of human MSCs."  Methods in Mol. Biol. 449: 93–107.

Reger, R.L., Wolfe, M.R. (2008)  "Freezing harvested hMSCs and recovery of hMSCs from frozen vials for subsequent expansion, analysis and experimentation."  Methods in Mol. Biol. 449: 109–116.

Ohtaki, H., Ylostalo J.H., Foraker, J.E., Robinson, A.P., Reger, R.L., Shioda, S., Prockop, D.J. (2008)  "Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses."  Proc Natl Acad Sci USA. 105(38): 14638-43.  Epub 2008 Sept. 15.